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Background/aim: Mucins, such as MUC1 and MUC5AC, are known for their protective and moisturizing role in intestinal epithelium.
Their expression is tightly controlled given their essential role in normal tissue homeostasis, whereas their deregulation leads to chronic
inflammation, and even cancer. This study aimed to assess the expression profiles of MUC1 and MUC5AC and their implications in
colorectal carcinogenesis.
Materials and methods: A retrospective study of 202 patients who underwent colorectal cancer (CRC) surgery was conducted. The
expression of MUC1 and MUC5AC was investigated by immunohistochemistry and reverse-transcription polymerase chain reaction
(RT-PCR). Statistical analysis of mucin expression pattern, as well as the clinicopathological criteria of the patients, was performed using
the chi-square test, survival curves were plotted using the Kaplan—Meier product-limit method, and differences between the survival
curves were tested using the log-rank test.
Results: The expression of both mucins was abnormally high in the tumor tissues for both mRNA and protein. MUC1 expression was
correlated with advanced cancer stages and lymph node metastases for both the mRNA (P < 0.016 and P < 0.002, respectively) and
protein level (P < 0.006 and P < 0.001, respectively). However, MUC5AC expression did not pinpoint any significant association between
the clinicopathological criteria, but patients who expressed MUC5AC showed an increase in overall survival (P < 0.009).
Conclusion: The expression of MUC1 might be a poor prognostic biomarker in CRC and could play a role in tumor transformation and
metastasis. However, MUC5AC expression might be a good prognostic in the Tunisian cohort.
Keywords: Colorectal cancer, MUC1, MUC5AC, immunohistochemistry, RT-PCR

1. Introduction
The mucosal surface of the gastrointestinal tract is covered
with mucus that is secreted by specialized epithelial cells,
known as goblet cells. This mucus serves to lubricate,
hydrate, and protect the epithelium against potential
hazards [1,2].
As major components of mucus, mucins are high
molecular weight glycoproteins, that heavily contain
a large number of O-linked oligosaccharides and few
N-glycan chains, linked to a protein backbone that is also
known as mucin core protein or MUC. Over the years,
many reports have highlighted the involvement of MUC
expression in the invasion and metastasis formation of
numerous malignancies, such as breast [3], gastric [4], and
pancreatic carcinomas [5].
To date, a total of 22 mucins have been identified and
classified into 2 subgroups: secreted and transmembrane

[6]. Some of these mucins have been deemed as reliable
prognostic biomarkers in many types of carcinoma
prognosis. Nevertheless, findings are sometimes
inconclusive, especially in colorectal cancer (CRC) [7,8].
Two mucin genes seem to be among the most studied in
colorectal carcinoma: MUC1 and MUC5AC [9–12].
The transmembrane mucin MUC1, located on
chromosome 1q21-24, can be found on the apical
surfaces of most epithelial cells, including those in the
breast, digestive, respiratory, and genitourinary tract [6].
The secreted mucin MUC5AC, situated on chromosome
11p15.5, is usually expressed in the stomach and respiratory
tract [13]. This mucin is normally absent in a healthy
colon, but frequently present in colorectal adenomas and
colon cancers [14]. Several researchers have reported an
increase of both MUC1 and MUC5AC expression when
compared to the normal mucosa [2,15]. Consequently,
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MUC1 could be a marker of poor prognosis, indicating
that its upregulation may be involved in CRC progression
[6,10]. In contrast, MUC5AC expression could be a good
marker of better prognosis, and it increases the overall
survival of patients [16].
Therefore, it was aimed to evaluate the expression
pattern of both MUC1 and MUC5AC in colorectal
carcinoma, using immunohistochemical and molecular
methods, to establish the possible links between their
expressions and colorectal carcinoma prognosis.
2. Materials and methods
2.1. Patients and tumor samples
This retrospective study comprised 202 Tunisian patients
who underwent CRC surgery between 2000 and 2017. The
study protocol was approved by the Ethics Committee of
Mongi Slim Hospital. The collected data included sex, age,
tumor localization, histological type, differentiation, and
tumor node metastasis (TNM) staging (stages I, II, III,
and IV). TNM staging was based on the American Joint
Committee on Cancer (AJCC) staging manual, eighth
edition [17].
2.2. Immunohistochemical study
The 2-protein expression was analyzed on 4-µm thick
formalin fixed paraffin-embedded samples. Slides were
incubated in an oven at 37 °C overnight, deparaffinized
in toluene, rehydrated in descending concentrations of
ethanol, and finally in double distilled water. Later, they
were immersed in citrate buffer (pH = 6), preheated in a
microwave for 5 min to unmask the epitopes, and then
kept at room temperature for 20 min, followed by a tris
washing.
Peroxidase block was used to inhibit endogenous
peroxidase activity. After washing 2 times in tris, MUC1
(monoclonal mouse anti-MUC1 protein antibody, catalog
NCL-MUC1, clone Ma695, dilution 1:100; Novocastra
Laboratories Ltd., Newcastle, UK) and MUC5AC
(monoclonal mouse anti-Muc5AC protein antibody,
catalog NCL-MUC5AC, clone CLH2, dilution 1:50;
Novocastra Laboratories Ltd.) were incubated at room
temperature for 1 h. After washing with tris, the sections
were incubated with a postprimary block for 30 min. The
revelation was conducted using 3,3’-diaminobenzidine
(DAB) chromogen (Liquid DAB + substrate chromogen
system; Novocastra Laboratories Ltd.), followed by nuclear
staining using hematoxylin.
2.3. RNA extraction and reverse transcriptase polymerase
chain reaction
RNA extraction was performed on 34 frozen specimens
taken from patients who underwent colorectal tumor
resection at the Department of Surgery, and on 168 archival
formalin-fixed, paraffin-embedded (FFPE) blocks, which
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were preserved at the Department of Pathology and
Cytology of Mongi Slim Hospital, in La Marsa, Tunisia.
With regards to the frozen specimens, the samples
were kept at –80 °C in RNA later stabilization solution
(Invitrogen, Thermo Fisher Scientific Inc., Carlsbad,
CA, USA). First, the fragments were homogenized
using a sterile, RNase-free mortar and pestle, and then
the homogenates were immediately transferred into
sterile, RNase-free microcentrifuge tubes that contained
Trizol reagent (Invitrogen). The total RNA isolation was
conducted as indicated in the manufacturer’s instructions,
using the PureLink® RNA mini kit (Invitrogen).
For the FFPE samples, 3–8 pieces of 10-mm sections
were placed into a sterile, RNase-free microcentrifuge tube
and total RNA isolation was performed using the PureLink
FFPE total RNA isolation kit (Invitrogen) according to the
manufacturer’s instructions. Following RNA purification
from both the frozen and FFPE specimens, a final DNase I
digestion (Invitrogen) was performed to remove genomic
DNA contamination.
The RNA was stored at –80 °C until used. RNA
concentration was determined using the Qubit RNA
HS assay kit (Thermo Fisher Scientific, Waltham, MA,
USA), and the quality was verified using an Agilent 2100
bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA,
USA), which analyzed 12 samples simultaneously, using
Agilent RNA nano chips. The Agilent 2100 Expert software
allows the automatic calculation of the RNA integrity
number (RIN), which has a value between 1 and 10, where
the higher this value is, the better the quality of RNA.
Hence, using the RIN scores, samples with the highest
value for both frozen and FFPE samples were chosen.
The cDNA was synthesized using M-MLV reverse
transcriptase (Invitrogen) in a 25 µL total volume reaction
that contained 200 ng of total RNA for each sample.
The 35-cycle amplification included 94 °C for 30 s; 63
°C for 30 s for MUC1 and 58 °C for 30 s for MUC5AC; and
72 °C for 30 s. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) served as an internal standard. The polymerase
chain reaction (PCR) primers for MUC1, MUC5AC, and
GAPDH are detailed in Table 1.
The reverse-transcription (RT)-PCR products were
verified on 2% agarose gel, and then stained with 0.1 mg/
mL of ethidium bromide to check the amplification of the
different genes under ultraviolet light.
After that, the MUC1 and MUC5AC PCR products
were analyzed using chip electrophoresis, and for that, the
Agilent DNA 1000 chip kit was used. All of the chips were
prepared according to the manufacturer’s instructions. It
should be noted here that both the size and concentration
of each separated band were automatically calculated
using the software of the 2100 bioanalyzer.
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Table 1. Primers and cycling parameters.
Sequence (5’-3’)
MUC1
F: CCAGCCCGGGATACCTACCAT
R: GCGACGTGCCCCTACAAGTT
MUC5AC
F: CCTTCGACGGACAGAGCTAC
R: TCTCGGTGACAACACGAAAG
GAPDH
F: GGGTGTGAACCATGAGAAGT
R: GACTGTGGTCATGAGTCCT

Annealing temperature (°C)

Product length (bp)

63

188

58

111

57

136

2.4. Statistical analysis
All of the clinicopathological criteria were analyzed
using IBM SPSS Statistics for Windows 20.0 (IBM
Corp., Armonk, NY, USA). Descriptive analysis and the
categorical variables were evaluated using the chi-square
test.
For overall survival, the expression profiles of MUC1 and
MUC5AC were analyzed simultaneously, and 4 phenotypes
were established, comprising MUC1+MUC5AC+, MUC1–
MUC5AC–, MUC1+MUC5AC–, and MUC1–MUC5AC+,
in addition to each gene separately.
Survival curves were plotted using the Kaplan–Meier
product-limit method, and differences between the
survival curves were tested using the log-rank test. P <
0.05 was accepted as statistically significant.
3. Results
The 202 patients comprised 110 males (54%) and 92
females (46%), with a male to female sex ratio of 1.19. The
average age was 60 years (ranging from 29 to 92 years).
Tumors were more frequently located in the left colon
(76%). Immunohistochemical study was performed on
samples of paraffin-embedded tissues from 202 CRC
patients.
Determined were 54 cases of mucinous adenocarcinoma
(27%), 28 cases of adenocarcinoma with mucinous
component (mucin formation <50%) (14%), and 120 cases
of nonmucinous carcinomas (59%). Normal colorectal
mucosa from tissue margins served as the controls. The
same samples were studied using RT-PCR, using both
the frozen (34 cases) and paraffin-embedded tissues (168
cases).
Histologically, the series consisted of 164 well
differentiated (81%), 30 moderately (15%), and 8 poorly
differentiated (4%) samples. TNM staging system showed
that 20 samples were stage I (10%), 80 were stage II (40%),
92 were stage III (45%), and 10 were stage IV (5%).

3.1. Immunohistochemistry expression of MUC1
Of the 202 samples of normal mucosa, 18 (9%) showed
positive staining for MUC1 in both the cytoplasm and
apical membrane (Figure 1a), whereas the remaining
samples reacted weakly or not at all (Figure 1b). MUC1
expression was remarkably increased in the tumoral tissue
when compared to the normal mucosa, where 88 of the
202 samples (44%) were positively stained in the apical
membrane and cytoplasm (Figure 2).
Positive MUC1 protein expression was determined in
54% of the stage III (50 of 92) and 60% of the stage IV (6 of
10) samples. In contrast, only 20% and 35%, respectively,
of the stage I (4 of 20) and stage II (28 of 80) samples were
positive.
Only 30% of the patients with no lymph node
metastases (N0) showed a positive signal for MUC1,
whereas those with lymph nodes N1, N2, and N3 showed
positive staining in 62%, 47% and 60% of the samples,
respectively. Statistical analysis of the MUC1 expression
pattern along with the clinicopathological criteria of the
patients showed that the signal positivity was strongly
associated with the advanced cancer stages (P < 0.006) and
lymph node metastasis (P < 0.001).
The results were summarized in Table 2.
3.2. Immunohistochemistry expression of MUC5AC
Since normal colorectal mucosa does not express
MUC5AC, gastric mucosa was used as the positive control.
The later showed a strong signal in the cytoplasm and the
apical membrane. MUC5AC exhibited a similar staining
pattern to that of MUC1 in terms of the membrane and
cytoplasm expression, which was observed in 30 of the 202
colorectal carcinomas samples (15%) (Figure 3). Statistical
analysis of the MUC5AC immunohistochemical results
compared with the different clinicopathological criteria
did not show any significant association. The results are
summarized in Table 2.
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Figure 1. (a) Membranous and cytoplasmic positive staining with anti-MUC1 in healthy distant colorectal tissue (MUC1 ×200); (b)
Absence of anti-MUC1 staining in healthy colorectal tissue (MUC1, ×400).

Figure 2. Positive staining with anti-MUC1 in the mucinous
adenocarcinoma (MA) (MUC1 ×400).

Figure 3. Positive staining with anti-MUC5AC in MA (MUC5AC
×200).

3.3. mRNA expression of MUC1 and MUC5AC in
colorectal carcinomas
MUC1 gene expression was assessed using RT-PCR,
revealing an amplicon of 188 bp in 48% of the samples
(96/202). For the MUC5AC gene, amplification
demonstrated that 40 of the 202 samples (20%) presented

an amplicon of 111 bp. GAPDH, the reference gene, was
successfully amplified in all of the samples (Figure 4).
A detailed analysis of all of the clinicopathological and
immunohistochemical criteria compared with the gene
molecular expressions was performed in order to identify
any particularities (Table 3). MUC1 was found to be highly
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Table 2. MUC1 and MUC5AC protein expression profiles based on the clinicopathological criteria of patients.

Clinicopathological
criteria

MUC1 immunostaining
Positive
n = 88

Negative
n = 114

≥60 (n = 120)

46

74

<60 (n = 82)

42

40

Male (n = 110)

50

60

Female (n = 92)

38

54

Right colon (n = 48)

16

32

Left colon (n = 154)

72

82

NMC (n = 120)

48

72

MA (n = 54)

26

28

MC (n = 28)

14

14

Well (n = 164)

74

90

Moderate (n = 30)

12

18

Poor (n = 8)

2

6

I (n = 20)

4

16

II (n = 80)

28

52

III (n = 92)

50

IV (n = 10)

6

N0 (n = 104)

32

72

N1 (n = 62)

38

24

N2 (n = 34) °)

16

N3 (n = 2)

2

MUC5AC immunostaining
P-value

Positive
n = 30

Negative
n = 182

16

104

14

68

20

90

10

82

10

38

20

134

P-value

Age (years)
0.070

0.463

Sex
0.554

0.146

Tumor location
0.102

0.182

Histological type
18

102

10

44

2

26

26

138

2

28

2

6

2

18

16

64

42

10

82

4

2

8

18

86

8

54

18

4

30

0

0

2

0.460

0.388

Differentiation
0.487

0.306

Stages
0.006

0.332

Lymph node metastasis
0.001

0.332

MA: mucinous adenocarcinoma, MC: mucinous component, NMC: nonmucinous carcinomas.

involved in the advanced stages (P < 0.016) and lymph node
metastasis (P < 0.002). Moreover, gene expression showed
a significant correlation with the immunohistochemical
results (P < 0.000). The MUC5AC statistical analysis
highlighted only an association between the molecular
expression and immunohistochemical profile (P < 0.000)
(Table 3).
3.4. Overall survival statistical analysis
Among the 202 patients, 24 were lost at follow-up; hence,
these patients were not included in the survival curve
analysis. The average overall survival rate of the 178
patients was 27 months (from 1 to 167 months). Among
the 178 patients, 78 were MUC1 positive (44%) and 26

were MUC5AC positive (15%). Moreover, 35% died during
follow-up (62 patients), 16 were MUC1+MUC5AC+, 90
were MUC1–MUC5AC–, 62 were MUC1+MUC5AC–, and
10 were MUC1–MUC5AC+. The death rates were 62.5%,
27%, 35.5%, and 60%, respectively.
Based on the expression profiles of MUC1 and MUC5AC
simultaneously, the test did not pinpoint any significant
association (P < 0.062). To further evaluate whether the
expression status of MUC1 or MUC5AC affected prognosis,
each gene was studied separately.
Among the 62 deceased patients, 32 expressed MUC1
(52%) and 16 expressed MUC5AC (26%). This percentage
might suggest that MUC5AC expression could be a good

313

HAZGUI et al. / Turk J Med Sci

Figure 4. Bioanalyzer gel image of MUC1 and MUC5AC
expression in the CRC tissues. Ladder at 1500 bp; MUC1 cDNA
(188 bp); MUC5AC cDNA (111 bp).

prognostic biomarker, unlike MUC1, but statistically, an
association was only found between MUC5AC expression
and overall survival (P < 0.009) (Figure 5). Patients who
expressed MUC5AC showed an increase in overall survival
when compared to those who did not.
4. Discussion
As the third most common cancer, CRC has been tagged
a preeminent public health concern and the main cause
for the exponential morbidity rate throughout the
world [18,19]. Mucins are large O-glycoproteins that are
expressed on epithelia, which provide a protective barrier
against mechanical, chemical, enzymatic, and microbial
damage in the aerodigestive and genitourinary systems
[20,21]. Mucin expression is tightly controlled, given
their essential role in normal tissue homeostasis, whereas
their deregulation leads to chronic inflammation, and
even cancer. It has been accepted that quantitative and
qualitative changes in mucins are not only a consequence,
but also potential contributors to inflammation and cancer
[15,22].
The current study focused on the evaluation of MUC1
and MUC5AC implication in CRC, and the exploration
of their possible use as markers in the detection and
treatment of this neoplasm. The results highlighted that
MUC1 and MUC5AC mRNA, and protein levels, were
notably upregulated in tumor tissues when compared with
the normal mucosa. A similar pattern was also found in
many other studies [2,10,15,23].
The immunohistochemical analysis showed the
presence of MUC1 in 9% of the studied normal mucosa. It
should be noted that this percentage is variable, since some
studies have reported a lack of MUC1 expression in normal
mucosa [10], while others have mentioned expression in
some or all of the studied cases [15,24].
As for adenocarcinomas, many studies have reported
a slight to moderate variation in the MUC1 expression
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profile. In contrast to some other research, where the gene
presence was noted in more than 80% of the cases, that
herein was 44% [10,15,25]. This variability may have been
attributed to either ethnicity and geographical distribution,
or the heterogeneous designs of these studies (number of
samples, sampling methods, tumor sites, tumor stages) [2].
In literature, the high expression of MUC1 positively
correlates with the stage, metastasis, poor tumor
differentiation, and even worse, long-term survival [10,26–
29]. The statistical analysis of the immunohistochemical
profiles and mRNA expression of the patients herein
showed that MUC1 expression was relatively associated
with advanced stages and lymph node metastasis [25,26].
Several studies have indicated MUC1 involvement
in colorectal carcinoma progression and metastasis
development. One of the possible mechanisms is that this
mucin acts as a ligand for cell adhesion molecules, which
benefits the MUC1-expressing circulating tumor cells and
helps them to adhere to endothelial cells, and therefore,
allows their migration into secondary sites [2,27].
Under normal physiological conditions, secretory
mucin MUC5AC is not expressed in the colonic mucosa,
whereas its aberrant expression is observed during the
development of colon cancer [1,13,15,23,30]. Since
MUC5AC is not expressed in normal colon mucosa,
gastric mucosa was used as the positive control. However,
MUC5AC protein was found in 15% of the colorectal
carcinomas (30/202), and similar results were published
in other studies with varying percentages [10,13,15,21,31–
33]. Although the current results regarding MUC5AC
were in accordance with the aforementioned findings, its
expression did not serve as a statistically significant marker
of tumor progression.
Regarding the mRNA expression, most of the samples
with positive RT-PCR amplification showed positive
immunohistochemical staining of the studied gene. Note
that in some cases, the protein was not found, despite the
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Table 3. MUC1 and MUC5AC mRNA expression profiles based on the clinicopathological criteria of patients.
MUC1 mRNA
Clinicopathological criteria

Positive
n = 96

MUC5AC mRNA
Negative
n = 106

P-value

Positive
n = 40

Age (years)

Negative

P-value

n = 172

≥60 (n = 120)

53

67

<60 (n = 82)

43

39

22

98

18

64

Male (n = 110)

56

54

24

86

Female (n = 92)

40

52

16

76

Right colon (n = 48)

18

30

14

34

Left colon (n = 154)

78

76

26

128

NMC (n = 120)

53

67

MA (n = 54)

29

25

23

97

13

41

MC (n = 28)

14

14

4

24

Well (n = 164)

81

83

Moderate (n = 30)

13

17

34

130

4

26

Poor (n = 8)

2

6

2

6

I (n = 20)

5

15

3

17

II (n = 80)

32

48

20

60

III (n = 92)

53

39

15

77

IV (n = 10)

6

4

2

8

N0 (n = 104)

37

67

23

81

N1 (n = 62)

39

23

13

49

N2 (n = 34) °)

18

16

4

30

N3 (n = 2)

2

0

0

2

0.248

0.526

Sex
0.292

0.432

Tumor location
0.111

0.062

Histological type
0.487

0.552

Differentiation
0.356

0.602

Stages
0.016

0.501

Lymph node metastasis

IHC profile

0.002

0.000

0.516

0.000

Positive

88

0

30

0

Negative

8

106

10

162

IHC: Immunohistochemistry.

presence of mRNA (8 samples with MUC1 and 10 samples
with MUC5AC). The discordance between the transcript
and protein expression levels probably would have been
due to posttranscriptional mechanisms [34,35].
In the current study, it was not possible to find
statistically significant relationships between the expression
profiles of MUC1 and MUC5AC simultaneously, and the
survival of patients with CRC (P < 0.062). The analysis of
each gene separately showed that patients who expressed

MUC5AC had a better survival rate (P < 0.009). For MUC1,
the evaluation was not significant (P < 0.889).
For MUC5AC, many studies have revealed that tumors
with a negative expression of MUC5AC showed a worse
prognosis when compared with tumors when MUC5AC
was positive, while others studies have had the opposite
result or did not pinpoint any correlations [1,9,30]. This
supports the idea that the presence of MUC5AC can be a
prognostic factor for nonaggressive colorectal carcinomas
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Figure 5. Patient survival curve.

and a promising target in the treatment of colon cancer
[23].

the findings and predict the clinical usefulness of these
molecular markers.

5. Conclusion
The expression of MUC1 might be a biomarker for
poor prognosis in CRC and could play a role in tumor
transformation and metastasis. However, the expression
of MUC5AC might have been a better prognostic in the
Tunisian cohort. Given the importance of such analyses,
future studies can be focused on the evaluation of other
mucins, such as MUC2 and MUC4, to demonstrate
the involvement of their expression and establish a
combination between them in colorectal carcinoma.
Nonetheless, further investigation, in larger patient
groups and with other techniques, is required to confirm
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